FDA approves nivolumab for adjuvant Stage IIB/C melanoma treatmentNov 10Regulatory decisionBristol Myers Squibbnivolumab
FDA grants accelerated approval to Rybrevant Faspro for head and neck cancerNov 5Regulatory decisionamivantamab and hyaluronidase-lpujamivantamab-vmjw
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
argenx to present Phase 3 ALKIVIA myositis data at ACR Convergence 2026Oct 19Publicationargenxefgartigimod
J&J reports Q3 2026 results, raises full-year sales and EPS guidanceOct 13Quarterly updateJohnson & Johnson
FDA clears atezolizumab combo for Stage III dMMR colon cancerOct 8Regulatory decisionatezolizumabatezolizumab and hyaluronidase-tqjs
Takeda posts results for TAK-881 vs HYQVIA pharmacokinetic study in PIDD patientsSep 30Trial updateTakeda Pharmaceutical Co Ltd
Pfizer posts MET097 obesity results; registers new Phase 3 obesity and dermatitis trialsAug 28Weekly roundup, 6 itemsberobenatidePF-08154225
Halozyme posts record Q2 2026, raises full-year guidance on royalty growthAug 6Quarterly updateHalozyme Therapeutics